Haloperidol decanoate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461008

CAS#: 74050-97-8

Description: Haloperidol decanoate is a typical antipsychotic drug used as maintenance therapy for schizophrenia and mood disorders formulated as an ester for intramuscular injection.


Chemical Structure

img
Haloperidol decanoate
CAS# 74050-97-8

Theoretical Analysis

MedKoo Cat#: 461008
Name: Haloperidol decanoate
CAS#: 74050-97-8
Chemical Formula: C31H41ClFNO3
Exact Mass: 529.28
Molecular Weight: 530.120
Elemental Analysis: C, 70.24; H, 7.80; Cl, 6.69; F, 3.58; N, 2.64; O, 9.05

Price and Availability

Size Price Availability Quantity
5mg USD 300 2 Weeks
10mg USD 550 2 Weeks
25mg USD 950 2 Weeks
Bulk inquiry

Synonym: Haloperidol decanoate; Haldol; Neoperidole; KD 136; KD 16; KD-136; R 13,672; R 13672; R-13,672;

IUPAC/Chemical Name: 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)piperidin-4-yl decanoate

InChi Key: GUTXTARXLVFHDK-UHFFFAOYSA-N

InChi Code: InChI=1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

SMILES Code: CCCCCCCCCC(OC1(C2=CC=C(Cl)C=C2)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 530.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jann MW, Penzak SR. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. CNS Drugs. 2018 Mar;32(3):241-257. doi: 10.1007/s40263-018-0508-6. Review. Erratum in: CNS Drugs. 2018 Jun 2;:. PubMed PMID: 29569082.

2: Geerts H, Spiros A, Roberts P, Alphs L. A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly. Schizophr Res. 2018 Jan 25. pii: S0920-9964(17)30711-9. doi: 10.1016/j.schres.2017.11.016. [Epub ahead of print] PubMed PMID: 29395607.

3: Emsley R, Parellada E, Bioque M, Herrera B, Hernando T, García-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2018 Jan;33(1):15-33. doi: 10.1097/YIC.0000000000000195. PubMed PMID: 28817397.

4: Dekkers BGJ, Eck RJ, Ter Maaten JC, Touw DJ. An acute oral intoxication with haloperidol decanoate. Am J Emerg Med. 2017 Sep;35(9):1387.e1-1387.e2. doi: 10.1016/j.ajem.2017.07.013. Epub 2017 Jul 5. PubMed PMID: 28705742.

5: Decuypere F, Sermon J, Geerts P, Denee TR, De Vos C, Malfait B, Lamotte M, Mulder CL. Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study. PLoS One. 2017 Jun 14;12(6):e0179049. doi: 10.1371/journal.pone.0179049. eCollection 2017. PubMed PMID: 28614404; PubMed Central PMCID: PMC5470699.

6: Khan AY, Salaria S, Ovais M, Ide GD. Depot antipsychotics: Where do we stand? Ann Clin Psychiatry. 2016 Nov;28(4):289-298. Review. PubMed PMID: 27901520.

7: Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, Furukawa TA, Baldessarini RJ, Lim BP, Sim K. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016 Feb 5;2(1):59-66. eCollection 2016 Jan. PubMed PMID: 27703755; PubMed Central PMCID: PMC4995551.

8: Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France]. Encephale. 2017 Aug;43(4):311-320. doi: 10.1016/j.encep.2016.02.021. Epub 2016 Sep 9. French. PubMed PMID: 27623123.

9: Lister J, Andreazza AC, Navaid B, Wilson VS, Teo C, Nesarajah Y, Wilson AA, Nobrega JN, Fletcher PJ, Remington G. Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jan 4;72:23-29. doi: 10.1016/j.pnpbp.2016.08.010. Epub 2016 Aug 24. PubMed PMID: 27565433.

10: Madhusoodanan S, Steinberg LR, Coleman A, Bavli S. Hyperprolactinemia Secondary to Pituitary Microadenoma Versus Haloperidol- A Diagnostic Enigma. A Case Report and Brief Review. Curr Drug Saf. 2017;12(1):19-21. doi: 10.2174/1574886311666160719151206. Review. PubMed PMID: 27440143.

11: Rosenheck RA, Leslie DL, Sint KJ, Lin H, Li Y, McEvoy JP, Byerly MJ, Hamer RM, Swartz MS, Stroup TS. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. Psychiatr Serv. 2016 Oct 1;67(10):1124-1130. Epub 2016 Jun 1. PubMed PMID: 27247177; PubMed Central PMCID: PMC5048499.

12: Scangos KW, Caton M, Newman WJ. Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report. J Clin Psychopharmacol. 2016 Jun;36(3):283-5. doi: 10.1097/JCP.0000000000000505. PubMed PMID: 27035492.

13: Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France. Pharmacoeconomics. 2016 Apr;34(4):363-91. doi: 10.1007/s40273-015-0348-x. PubMed PMID: 26883132; PubMed Central PMCID: PMC4796324.

14: Kalicharan RW, Schot P, Vromans H. Fundamental understanding of drug absorption from a parenteral oil depot. Eur J Pharm Sci. 2016 Feb 15;83:19-27. doi: 10.1016/j.ejps.2015.12.011. Epub 2015 Dec 9. PubMed PMID: 26690043.

15: Denee TR, Geerts P, Sermon J, Decuypere F, Widrich C, Rijntjes R, Mulder CL. Treatment Continuation And Treatment Characteristics Of Four Long Acting Antipsychotic Medications (Paliperidone Palmitate, Risperidone Microspheres, Olanzapine Pamoate And Haloperidol Decanoate) In The Netherlands. Value Health. 2015 Nov;18(7):A407. doi: 10.1016/j.jval.2015.09.960. Epub 2015 Oct 20. PubMed PMID: 26532297.

16: Matthew BJ, Gedzior JS. Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate. Int J Psychiatry Med. 2015;50(4):405-11. doi: 10.1177/0091217415612736. Epub 2015 Nov 2. PubMed PMID: 26526398.

17: Ostuzzi G, Barbui C. Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study. Epidemiol Psychiatr Sci. 2016 Feb;25(1):21-3. doi: 10.1017/S2045796015000980. Epub 2015 Oct 30. PubMed PMID: 26515607.

18: Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J Manag Care Spec Pharm. 2015 Sep;21(9):754-68. PubMed PMID: 26308223.

19: Chou YH, Chu PC, Wu SW, Lee JC, Lee YH, Sun IW, Chang CL, Huang CL, Liu IC, Tsai CF, Yen YC. A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder. Clin Psychopharmacol Neurosci. 2015 Aug 31;13(2):121-8. doi: 10.9758/cpn.2015.13.2.121. PubMed PMID: 26243837; PubMed Central PMCID: PMC4540044.

20: Kippe JM, Mueller TM, Haroutunian V, Meador-Woodruff JH. Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia. Schizophr Res. 2015 Aug;166(1-3):219-24. doi: 10.1016/j.schres.2015.06.002. Epub 2015 Jun 20. PubMed PMID: 26104473; PubMed Central PMCID: PMC4512847.